Glaxosmithkline Dividends - GSK

Glaxosmithkline Dividends - GSK

Buy
Sell
Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
£62.08
Silver
Monthly Subscription
for only
£17.37
UK/US Silver
Monthly Subscription
for only
£30.59
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Glaxosmithkline Plc GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change Price Change % Stock Price Last Trade
13.00 0.94% 1,391.60 15:12:11
Open Price Low Price High Price Close Price Previous Close
1,385.00 1,382.00 1,396.20 1,378.60
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Glaxosmithkline GSK Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount
05/02/2020FinalGBX2331/12/201831/12/201920/02/202021/02/202009/04/202080
30/10/20191GBX1931/12/201831/12/201914/11/201915/11/201909/01/20200
24/07/20191GBX1931/12/201831/12/201908/08/201909/08/201910/10/20190
01/05/20191GBX1931/12/201831/12/201916/05/201917/05/201911/07/20190
06/02/2019FinalGBX2331/12/201731/12/201821/02/201922/02/201911/04/201980
31/10/20181GBX1931/12/201731/12/201815/11/201816/11/201810/01/20190
25/07/20181GBX1931/12/201731/12/201809/08/201810/08/201811/10/20180
25/04/20181GBX1931/12/201731/12/201810/05/201811/05/201812/07/20180
07/02/2018FinalGBX2331/12/201631/12/201722/02/201823/02/201812/04/201880
25/10/20171GBX1931/12/201631/12/201709/11/201710/11/201711/01/20180
26/07/20171GBX1931/12/201631/12/201710/08/201711/08/201712/10/20170
26/04/20171GBX1931/12/201631/12/201711/05/201712/05/201713/07/20170
08/02/2017FinalGBX2331/12/201531/12/201623/02/201724/02/201713/04/201780
26/10/20161GBX1931/12/201531/12/201603/11/201604/11/201612/01/20170
27/07/20161GBX1931/12/201531/12/201611/08/201612/08/201613/10/20160
27/04/20161GBX1931/12/201531/12/201612/05/201613/05/201614/07/20160
03/02/2016SpecialGBX2031/12/201431/12/201518/02/201619/02/201614/04/20160
03/02/2016FinalGBX2331/12/201431/12/201518/02/201619/02/201614/04/2016100
19/10/20151GBX1931/12/201431/12/201512/11/201513/11/201514/01/20160
29/07/20151GBX1931/12/201431/12/201513/08/201514/08/201501/10/20150
06/05/20151GBX1931/12/201431/12/201514/05/201515/05/201509/07/20150
04/02/2015FinalGBX2331/12/201331/12/201419/02/201520/02/201509/04/201580
22/10/20141GBX1931/12/201331/12/201406/11/201407/11/201408/01/20150
24/07/20141GBX1931/12/201331/12/201406/08/201408/08/201402/10/20140
30/04/20141GBX1931/12/201331/12/201414/05/201416/05/201410/07/20140
05/02/2014FinalGBX2331/12/201231/12/201319/02/201421/02/201410/04/201478
23/10/20131GBX1931/12/201231/12/201313/11/201315/11/201309/01/20140
24/07/20131GBX1831/12/201231/12/201307/08/201309/08/201303/10/20130
24/04/20131GBX1831/12/201231/12/201308/05/201310/05/201311/07/20130
06/02/2013FinalGBX2231/12/201131/12/201220/02/201322/02/201311/04/201374
31/10/20121GBX1831/12/201131/12/201214/11/201216/11/201203/01/20130
25/07/20121GBX1731/12/201131/12/201208/08/201210/08/201204/10/20120
25/04/20121GBX1731/12/201131/12/201209/05/201211/05/201205/07/20120
07/02/2012SpecialGBX531/12/201031/12/201115/02/201217/02/201212/04/20120
07/02/2012FinalGBX2131/12/201031/12/201115/02/201217/02/201212/04/201275
26/10/2011InterimGBX1731/12/201031/12/201102/11/201104/11/201105/01/20120
26/07/2011InterimGBX1631/12/201031/12/201103/08/201105/08/201106/10/20110
27/04/2011InterimGBX1631/12/201031/12/201104/05/201106/05/201107/07/20110
03/02/2011FinalGBX1931/12/200931/12/201009/02/201111/02/201107/04/201165
21/10/2010InterimGBX1631/12/200931/12/201027/10/201029/10/201006/01/20110
21/07/2010InterimGBX1531/12/200931/12/201028/07/201030/07/201007/10/20100
28/04/2010InterimGBX1531/12/200931/12/201005/05/201007/05/201008/07/20100
04/02/2010FinalGBX1831/12/200831/12/200910/02/201012/02/201008/04/201061
29/10/20091GBX1531/12/200831/12/200904/11/200906/09/200907/01/20100
30/07/20091GBX1431/12/200831/12/200931/07/200931/07/200908/10/200928
22/04/20091GBX1431/12/200831/12/200929/04/200901/05/200909/07/20090
05/02/2009FinalGBX1731/12/200731/12/200811/02/200913/02/200909/04/200957
22/10/20081GBX1431/12/200731/12/200829/10/200831/10/200809/01/20080
07/02/2008FinalGBX1331/12/200631/12/200713/02/200815/02/200810/04/200853
25/07/20071GBX1231/12/200631/12/200701/08/200703/08/200711/10/20070
24/04/20071GBX1231/12/200631/12/200702/05/200704/05/200712/07/20070
08/02/20071GBX1431/12/200531/12/200614/02/200616/02/200612/04/20070
08/02/2007FinalGBX031/12/200531/12/200601/01/197001/01/197001/01/197048
26/10/20061GBX1231/12/200531/12/200601/11/200603/11/200604/01/20070
26/07/20061GBX1131/12/200531/12/200602/08/200604/08/200605/10/20060
27/04/20061GBX1131/12/200531/12/200610/05/200612/05/200606/07/20060
08/02/2006FinalGBX1431/12/200431/12/200515/02/200617/02/200606/04/200644
27/10/20051GBX1031/12/200431/12/200502/11/200504/11/200505/01/20060
29/07/20051GBX1031/12/200431/12/200503/08/200505/08/200506/10/20050
28/04/20051GBX1031/12/200431/12/200511/05/200513/05/200507/07/20050
10/02/2005FinalGBX1231/12/200331/12/200416/02/200518/02/200507/04/200542
28/10/20041GBX1031/12/200331/12/200403/11/200405/11/200406/01/20050
27/07/20041GBX1031/12/200331/12/200412/05/200414/05/200401/07/20040
27/07/20041GBX1031/12/200331/12/200404/08/200406/08/200430/09/20040
12/02/2004FinalGBX1431/12/200231/12/200318/02/200420/02/200415/04/200441
11/02/20041GBX931/12/200231/12/200329/10/200331/10/200306/01/20040
23/07/20031GBX931/12/200231/12/200330/07/200301/08/200302/10/20030
30/04/20031GBX931/12/200231/12/200307/05/200309/05/200303/07/20030
12/02/2003FinalGBX1331/12/200131/12/200219/02/200321/02/200317/04/200340
23/10/20021GBX930/03/200230/09/200230/10/200201/11/200203/01/20030
24/07/20021GBX930/12/200130/06/200231/07/200202/08/200203/10/20020
25/04/20021GBX901/10/200131/03/200201/05/200203/05/200204/07/20020
14/02/2002FinalGBX1231/12/200031/12/200120/02/200222/02/200218/04/200239
23/10/20011GBX930/09/200030/09/200131/10/200102/11/200103/01/20020
24/07/20011GBX930/06/200030/06/200101/08/200103/08/200104/10/20010
24/04/20011GBX931/03/200031/03/200102/05/200104/05/200105/07/20010
13/12/2000FinalGBX2331/12/199931/12/200018/12/200022/12/200017/04/200138
27/07/2000InterimGBX1530/12/199930/06/200007/08/200011/08/200016/10/20000
16/02/2000FinalGBX2231/12/199831/12/199928/02/200003/03/200025/05/200037
29/07/1999InterimGBX1530/12/199830/06/199909/08/199913/08/199901/10/19990
18/02/1999FinalGBX2131/12/199731/12/199801/03/199905/03/199920/05/199936

Top Dividend Posts

DateSubject
25/11/2020
14:12
garycook: MT,GSK dividend credited to my HL FSA & SIPP every 13 weeks.Could easily buy the ADVFN Premium service,but got warned for copy/pasting.So i want ADVFN to give me Premium for free.Can you have a word my fellow ramping friend LOL
24/11/2020
16:59
tradermichael: GSK are currently developing vaccines with 3 partners, Sanofi, Medicago and Clover. Each is using a GSK adjuvant. The Sanofi/GSK vaccine entered clinical trials in September 2020. They anticipate first results in December 2020 and to start a phase 3 study before the end of the year. If the clinical trials are successful, they will request regulatory approval in the first half of 2021. Medicago can support the production of large amounts of vaccine in a significantly shortened timeline. The vaccine candidate entered phase 2/3 clinical trials in mid-November 2020 and, if successful, they aim to make the vaccine available, in the first half of 2021. With Clover, their COVID-19 vaccine candidate, which moved into phase 1 clinical trials in June 2020 and is expected to enter late stage clinical trials before the end of the year.
23/11/2020
08:56
montyhedge: Even good news from GSK, if the market rotation from healthcare into say airlines good luck to them.https://www.gsk.com/en-gb/media/press-releases/gsk-starts-phase-3-study-of-rsv-maternal-candidate-vaccine/
12/11/2020
13:22
speedsgh: Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate - HTTPS://www.investegate.co.uk/glaxosmithkline-plc--gsk-/rns/medicago-gsk-phase-2-3-study-start/202011121300041549F/ · The COVID-19 vaccine candidate will contain GSK's pandemic adjuvant · Phase 3 part of clinical trial to enrol over 30,000 volunteers worldwide Medicago, a biopharmaceutical company headquartered in Quebec City, and GSK are pleased to announce the start of Phase 2/3 clinical trials of its plant-derived vaccine candidate for COVID-19 to evaluate its efficacy, safety, and immunogenicity. Based on the positive Phase 1 results, Medicago has decided to launch the Phase 2/3 clinical trial with GSK's pandemic adjuvant. Nathalie Landry, Executive Vice President, Scientific and Medical Affairs at Medicago, said: "Our Phase 1 results of the adjuvanted vaccine candidate were very encouraging and fully support further clinical evaluation." Thomas Breuer, Chief Medical Officer GSK Vaccines said: "This is the first of several GSK COVID-19 vaccine candidate collaborations to start Phase 2/3 clinical testing and an important step forward in our contribution to the global fight against the pandemic. We are delighted with the very promising Phase 1 results of Medicago's COVID-19 vaccine candidate in combination with GSK's pandemic adjuvant. Proven dose sparing and a high immune response due to GSK's adjuvant make us confident of delivering an efficacious vaccine with an acceptable safety profile in collaboration with Medicago."
11/11/2020
11:44
spud: 3 falling shares with recovery potential? ITV, GSK and Imperial Brands http://investomania.co.uk/2020/11/3-falling-shares-with-recovery-potential-itv-gsk-and-imperial-brands/ Shares in ITV plc (LON:ITV) (ITV.L), GlaxoSmithKline plc (LON:GSK) (GSK.L) and Imperial Brands PLC (LON:IMB) (IMB.L) have fallen since the start of 2020. Could they deliver recoveries over the long run? The ITV share price is down by around 40% since the start of this year. The company’s performance has been severely hurt by a slowing UK economy. As a cyclical business, it’s not a major surprise to me that the company has experienced slowing demand for advertising while business and consumer confidence is at a very low level. I’ve been impressed with the way in which ITV has responded to difficult trading conditions this year. I think its decision to reduce costs, invest in digital growth opportunities and press ahead with innovative plans such as its marketing opportunities show that it has the potential to expand its presence in a variety of mediums in the long run. I’m not expecting a quick recovery for the ITV share price. I’m cautious about the UK’s economic outlook over the next few months. But I do think that it has the capacity to post improving performance over the long run. The GSK share price has surprised me a little this year. The company’s investor updates have generally been pretty positive, to my mind. For instance, its consumer healthcare segment has performed well and this has largely offset a disappointing performance in its vaccine segment. I also have held the view for many years that GSK is a relatively defensive stock. However, it’s 17% decline since the start of this year suggests that this may not be entirely true. Over the long run, I’m upbeat about the prospects for the GSK share price. I think its plans to separate into two companies are sensible and have been mooted for many years. I’m also of the view that it’s 5%+ dividend yield could become more attractive as dividend growth opportunities move more in focus. The Imperial Brands share price has declined yet further this year. It’s down by another 30% in 2020 after a very challenging 2019. A change in management could spark a recovery in my opinion. However, I think it could take time for the company to reorganise, refresh its strategy and deliver improving financial performance. That said, I think the non-combustible segment offers longer term growth potential for companies such as Imperial Brands. Its existing cigarette brands may also provide the necessary cash flow to make investments in new growth areas as consumer trends continue to move towards less harmful alternatives to cigarettes. I’m not expecting the Imperial Brands share price to quickly recover. Neither am I expecting it to outperform the FTSE 100 in the short run. But, as a long-term investor, I think it is a more attractive business than its recent share price performance suggests. Disclosure: the author has no position in any stocks mentioned. spud
26/10/2020
13:08
geckotheglorious: GlaxoSmithKline, AnaptysBio amend immuno-oncology pact AnaptysBio (NASDAQ:ANAB) and GlaxoSmithKline ;(NYSE:GSK) have amended their immuno-oncology collaboration agreement that now provides AnaptysBio with increased royalties on dostarlimab sales, a royalty on GSK’s Zejula and a one-time cash payment. Previously, dostarlimab royalties ranged from 4-8%, where the 8% royalty tier was applicable to global net sales above $1B. Now the royalty terms range from 8-25%, where AnaptysBio will receive 8% of annual global net sales below $1B, and 12-25% of net sales above $1B. Starting January 1, 2021, GSK has also agreed to pay AnaptysBio a 1% royalty on GSK’s Zejula sales, and will pay a one-time cash payment of $60M within 30 days. GSK receives freedom to conduct combination development and commercialization of Zejula with third party molecules. hTTps://seekingalpha.com/news/3625707-glaxosmithkline-anaptysbio-amend-immuno-oncology-pact
22/10/2020
07:49
nimbo1: Dire performance, and investors take it on the chin because of the 5% divi... one of the greatest cons the investment community peddles in this country are that high dividend yields are good. You want wealth preservation and capital growth you have to listen to fund managers like Terry smith imo. That being said I might buy some GSK if it looks to be turning - have owned it several times and it pains me to see it in the doldrums as its an important UK company!
22/10/2020
07:32
tradermichael: (Alliance News) - Berenberg on Tuesday predicted GlaxoSmithKline's third-quarter performance to lag behind market expectations but said it was "encouraged" as the pharmaceutical firm heads towards the end of a difficult year. The German bank expects GSK to post third-quarter sales of GBP8.75 billion, which would be 6.8% lower annually and slightly below market forecasts of GBP8.80 billion. Consensus says adjusted earnings per share will come in at 30.5 pence for the three months ended September, although Berenberg predicted an adjusted EPS of 30.0p. GSK posted an adjusted EPS of 38.6p in the third quarter of 2019, so should Berenberg's forecast be correct, GSK will post a 22% annual fall in earnings. Berenberg rates GSK at Buy, with a GBP18.00 price target. The stock was down 0.6% at 1,388.40 pence each in London on Tuesday afternoon. GSK will report its quarterly results on Wednesday next week. "Since we initiated coverage on EU/US large cap pharma, our Buy rating on GlaxoSmithKline has been the most hotly debated topic. A near-term pushback has been downside risk to third quarter consensus and 2020 guidance," Berenberg explained. "Although we see some flexibility on research & development expenses and selling, general and administrative expense spend (Covid-19-related savings), the second quarter and third quarter gap in vaccine demand leaves existing 2020 EPS growth guidance challenging. But this is a short-lived issue." Berenberg noted GSK is guiding between a 1% and 4% decline in EPS in 2020, at constant currency. Berenberg itself expects a 5% decline. The German bank is optimistic about GSK's pipeline, though did note that there has also been investor debate about its quality. "Another investor debate centres on the quality of the pipeline. Our return on R&D investment analysis yields an average return for GlaxoSmithKline broadly in line with the peer group and cost of capital. Importantly, however, the trend is improving. We believe that at least five assets due to report proof-of-concept data next year could bring further upside and reinvigorate the story. Investor expectations remain very low," Berenberg said. "As we move towards the end of what was always going to be a tough year for GlaxoSmithKline, we remain encouraged by the direction of travel. US Shingrix prescriptions have demonstrated a strong rebound since the summer," the broker added, referring to a shingles vaccine. Berenberg expects GSK to return to EPS growth in the fourth quarter "and into 2021". Copyright 2020, Alliance News
14/10/2020
09:38
tradermichael: 4 weeks to go till holders qualify for next GSK dividend..... ;0)
11/10/2020
10:33
poikka: "If this is correct GSK is way behind" It ain't quite that simple: "We are collaborating with companies and research groups across the world working on promising COVID-19 vaccine candidates through the use of our innovative vaccine adjuvant technology. The use of an adjuvant is of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protecting more people. We announced on 14 April that GSK has joined forces with Sanofi, bringing together two of the world’s largest vaccines companies in an unprecedented collaboration to fight COVID-19. The two companies combined their innovative technologies to develop an adjuvanted COVID-19 vaccine, which entered clinical trials in September 2020. If successful and subject to regulatory considerations, we aim to complete the development required for availability by the second half of 2021. This would be a significantly faster timeline than for normal vaccine development and teams from both companies are working on this urgently. One of the important parts of this collaboration is our combined scale. Both companies bring significant manufacturing capacity and whilst we have a lot of work to do, given this is at an early-stage of development, we believe that, if successful, we will be able to make hundreds of millions of doses annually by the end of next year. Both GSK and Sanofi have a long history of making our vaccines available to people all around the world and we are committed to making any vaccine that is developed through this collaboration affordable and through mechanisms that offer fair access for all people. In addition to Sanofi, we are also collaborating with the University of Queensland, Clover Biopharmaceuticals and Xiamen Innovax Biotech Co., Ltd. We believe that more than one vaccine will be needed and we’re hoping that there will be a number of successful vaccines developed with our pandemic adjuvant technology. On 19 June, the scientific collaboration with Clover, using GSK’s pandemic adjuvant in combination with COVID-19 vaccine candidate SCB-2019, moved into phase I clinical trials. Over the next few months we expect to see data from many of these collaborations. On 7 July, we announced a new collaboration with Canadian biopharmaceutical company, Medicago, to develop and evaluate a COVID-19 candidate vaccine combining Medicago’s recombinant Coronavirus Virus-Like Particles (CoVLP) with GSK’s pandemic adjuvant system. CoVLPs mimic the structure of the virus responsible for COVID-19 disease, allowing them to be recognised by the immune system. The companies will use Medicago’s innovative plant-based production technology to manufacture the COVID-19 vaccine antigen. The vaccine candidate will enter into Phase I clinical trials in mid-July. How can plant based vaccines technology help fight COVID-19?How can plant based vaccines technology help fight COVID-19? How can plant based vaccines technology help fight COVID-19? This innovative technology uses the leaves of a plant as bioreactors to produce the protein for use in the CoVLP vaccine candidate. It is highly scalable and can support the production of large amounts of vaccine in a significantly shortened timeline. We have confirmed our intention to manufacture 1 billion doses of our pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted COVID-19 vaccine candidates. This follows completion of a review conducted across our global supply network. We will manufacture, fill and finish adjuvant for use in COVID-19 vaccines at sites in the UK, US, Canada and Europe. Overall GSK does not expect to profit from our portfolio of collaborations for COVID-19 vaccines during this pandemic. As any short-term profit generated will be invested in support of coronavirus related research and long-term pandemic preparedness, either through GSK’s internal investments, or with external partners. Making our adjuvant available to the world’s poorest countries will also be a key part of our efforts, including donations of this adjuvant, by working with governments and the global institutions that prioritise access. What is an adjuvant? An adjuvant is added to some vaccines to enhance the immune response, thereby creating a stronger and longer lasting immunity against infections than the vaccine alone. The use of an adjuvant is of particular importance in a pandemic situation since it can reduce the amount of antigen required per dose, allowing more vaccine doses to be produced and made available to more people."
ADVFN Advertorial
Your Recent History
LSE
GSK
Glaxosmith..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201126 15:27:14